SCHEMBL2014713

SCHEMBL2014713

O=CC1C=CC(=O)CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21259533 0.80
SCHEMBL2886239 0.80
SCHEMBL13295836 0.71
SCHEMBL3983475 0.69
SCHEMBL681879 0.69
SCHEMBL767441 0.69
SCHEMBL823130 0.68
SCHEMBL13244965 0.68 PTPN1 (0.33)
SCHEMBL11802419 0.68 ALDH1A1 (0.38)
SCHEMBL11802415 0.68 ALDH1A1 (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130065897-A1 COMPOUNDS, PREPARATION AND USES THEREOF PETER MACCALLUM CANCER INSTITUTE (AU) 2013-03-14 US disclosed
EP-2515903-A1 COMPOUNDS, PREPARATIONS AND USES THEREOF Peter MacCallum Cancer Institute (AU) 2012-10-31 EP disclosed
US-8273900-B2 Organic compounds NOVARTIS AG (CH) 2012-09-25 US disclosed
WO-2011075784-A1 COMPOUNDS, PREPARATIONS AND USES THEREOF PETER MACCALLUM CANCER INSTITUTE (AU) 2011-06-30 WO disclosed
US-20100035898-A1 Organic compounds NOVARTIS AG (CH) 2010-02-11 US disclosed